Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Plus Rituximab for R/R Marginal Zone Lymphoma
NCT06134284Phase 4Recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of orelabrutinib in marginal zone lymphoma (MZL). Started Jan 2023; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06134284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134284.